The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop ...

The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...

Management at Eli Lilly has expressed strong confidence in the growing demand for their obesity franchise and a robust pipeline of new products. The company is anticipating significant benefits from ...

The Health Resources and Services Administration has “invoked the nuclear option of removal from not only the 340B program ...

On this episode of Fortune’s Leadership Next podcast, host Diane Brady talks to Eli Lilly chair and CEO Dave Ricks. They ...

On Friday, Eli Lilly And Co (LLY) stock saw a decline, ending the day at $746.2 which represents a decrease of $-40.03 or -5.09% from the prior close of $786.23. The stock opened at $775.19 and ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

Barclays analyst Carter Gould maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $975.00.

Eli Lilly said the treatment, a once-daily pill called muvalaplin, showed reductions in Lp (a) levels compared to placebo. Injectables are currently in Phase 3 development, but "these are the first ...

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...